Esketamine - Auris Medical/INSERM/University of Montpellier

Drug Profile

Esketamine - Auris Medical/INSERM/University of Montpellier

Alternative Names: (s)-ketamine; AM-101; Esketamine otic gel; Keyzilen

Latest Information Update: 29 Jan 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Auris Medical; INSERM; University of Montpellier I
  • Developer Auris Medical
  • Class Analgesics; Antidepressants; Chlorobenzenes; Cyclohexanones; General anaesthetics; Small molecules
  • Mechanism of Action NMDA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Tinnitus

Most Recent Events

  • 28 Dec 2017 Auris Medical completes the phase III TACTT3 trial in Tinnitus in United Kingdom, Austria, Hungary, Germany, Belgium, Poland and Spain (Intratympanic) (NCT02040194)
  • 22 Sep 2017 Auris Medical completes enrolment in the phase III TACTT3 trial for Tinnitus in Austria, Belgium, Germany, Hungary, Poland, Spain, Switzerland, United Kingdom (Intratympanic)
  • 09 May 2017 Efficacy and adverse events data from the phase III AMPACT1 trial in Tinnitus released by Auris Medical
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top